Clinical Trial Update: Cladribine Tablets as an Exit Therapy Strategy

View source ↗

Summary

A clinical trial is evaluating cladribine tablets as an exit therapy strategy for multiple sclerosis, including relapsing-remitting and secondary progressive fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Progressive Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• MAVENCLAD (cladribine)

Snippet

Sponsor: University Hospital, Strasbourg, France | Conditions: Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis | Status: NOT_YET_RECRUITING